- Home
- GLUE
as of 01-08-2026 3:34pm EST
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.1B | IPO Year: | 2021 |
| Target Price: | $19.50 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $25.15 | Next Earning Date: | 11-06-2025 |
| Revenue: | $181,538,000 | Revenue Growth: | 1112.27% |
| Revenue Growth (this year): | 84.02% | Revenue Growth (next year): | -59.16% |
AI-Powered GLUE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
Chief Medical Officer
Avg Cost/Share
$15.17
Shares
3,155
Total Value
$47,861.35
Owned After
75,026
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$15.17
Shares
1,039
Total Value
$15,761.63
Owned After
22,693
SEC Form 4
President & CEO
Avg Cost/Share
$15.17
Shares
10,135
Total Value
$153,747.95
Owned After
624,403
SEC Form 4
Chief Business & Legal Officer
Avg Cost/Share
$15.17
Shares
3,155
Total Value
$47,861.35
Owned After
60,845
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$15.17
Shares
2,629
Total Value
$39,881.93
Owned After
62,371
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$15.17
Shares
3,155
Total Value
$47,861.35
Owned After
67,845
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Janku Filip | GLUE | Chief Medical Officer | Jan 5, 2026 | Sell | $15.17 | 3,155 | $47,861.35 | 75,026 | |
| Dunn Edmund | GLUE | Principal Accounting Officer | Jan 5, 2026 | Sell | $15.17 | 1,039 | $15,761.63 | 22,693 | |
| Warmuth Markus | GLUE | President & CEO | Jan 5, 2026 | Sell | $15.17 | 10,135 | $153,747.95 | 624,403 | |
| Nickson Philip | GLUE | Chief Business & Legal Officer | Jan 5, 2026 | Sell | $15.17 | 3,155 | $47,861.35 | 60,845 | |
| Champoux Jennifer | GLUE | Chief Operating Officer | Jan 5, 2026 | Sell | $15.17 | 2,629 | $39,881.93 | 62,371 | |
| Townson Sharon | GLUE | Chief Scientific Officer | Jan 5, 2026 | Sell | $15.17 | 3,155 | $47,861.35 | 67,845 |
Compare GLUE vs Leading Stocks
See how GLUE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.